TICKERNERD
Menu
RGNTHealthcare · Medical Instruments & Supplies

RGNT Stock Forecast: Regentis Biomaterials Ltd. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$1.81
+3.43% on the day

The 1 Wall Street analysts covering Regentis Biomaterials Ltd. hold a median 12-month price target of $10 — +452.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$12.7M
Ticker Nerd rank
8 / 100
Median analyst target
$10
Analysts covering
1
Total return, dividends reinvested
1W
−4.2%
1M
−9.0%
YTD
−73.1%
From high
−80.0%
From low
+41.4%
$1.28
$9.07
Range since 4 Dec 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

RGNT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regentis Biomaterials Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Issuance
61
Accruals
52
Revisions
25
Momentum
12
Growth
9
Quality
6
Value
2
Volatility
1

Size (91): Smaller than most of the companies we track.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGNT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGNT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 4 Dec 2025Adjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26RGNTHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +452.5% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGNT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RGNT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

RGNT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26RGNTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGNT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Regentis Biomaterials Ltd. (RGNT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−288.6%

Higher than 5% of US stocks

Return on assets
−113.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Regentis Biomaterials Ltd. (RGNT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Regentis Biomaterials Ltd. has a market value of $12.7M and an enterprise value of $3.8M.

  • Shares outstanding: 5.2M.

  • Regentis Biomaterials Ltd. employs 3 people.

market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

RGNT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RGNTRegentis Biomaterials Ltd.$12.7M
8
CUPRCuprina Holdings (Cayman) Ltd.$9.4M
4
LUCYInnovative Eyewear, Inc.$8.2M
20
BNGOBionano Genomics, Inc.$20.4M
78
RVPRetractable Technologies, Inc.$21.5M
60
FEMYFemasys, Inc.$21.7M
43
HBIOHarvard Bioscience, Inc.$35.6M
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regentis Biomaterials Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGNT news & analysis

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.

GlobeNewsWire · 18 Sept 2026neutral

IBN announced the release of the latest episode of The BioMedWire Podcast featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd. The episode is part of IBN's ongoing effort to distribute specialized content through widespread syndication channels.

Why it matters — A Regentis watcher would care because the podcast provides a platform for CEO Dr. Ehud Geller to communicate directly with the investment community about the company.

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

Accesswire · 11 Sept 2026positive

Regentis Biomaterials reported financial results for the six months ended June 30, 2026 and provided a corporate update. The company advanced its GelrinC U.S. pivotal trial with 43 patients treated and expects to complete enrollment by approximately year end 2026, expanded European commercialization readiness including surgeon training and regulatory approval of a new manufacturing process, and strengthened its balance sheet with a $6.5 million private placement in June 2026.

Why it matters — The update highlights meaningful clinical and commercial progress on GelrinC, a new manufacturing approval improving yield, and fresh capital that together signal tangible advancement toward commercialization for RGNT watchers.

FAQ

Frequently asked questions about RGNT stock

What is the RGNT stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Regentis Biomaterials Ltd. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RGNT stock a buy right now?

Of the 1 analysts covering Regentis Biomaterials Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Regentis Biomaterials Ltd. 8 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGNT?

As at 19 Sept 2026, Regentis Biomaterials Ltd. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will RGNT stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +452.5% from the last close, and Ticker Nerd's factor model ranks Regentis Biomaterials Ltd. 8 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RGNT stock forecast for 2030?

No analyst covering Regentis Biomaterials Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

What does Regentis Biomaterials Ltd. do?

Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions for damaged cartilage, bone, and other tissues.

What is the latest news on RGNT?

The most recent item we track (GlobeNewsWire, 18 Sept 2026): "IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.". IBN announced the release of the latest episode of The BioMedWire Podcast featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd. The episode is part of IBN's ongoing effort to distribute specialized content through widespread syndication channels.

Company

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions for damaged cartilage, bone, and other tissues. The company’s core platform, Gelrin, uses degradable hydrogel implants designed to support the regeneration of diseased or injured tissue, with a particular emphasis on orthopedic applications. Its lead product, GelrinC, is a cell-free, off-the-shelf hydrogel implant intended for knee cartilage repair, making it relevant to sports medicine and early-stage osteoarthritis care. Regentis Biomaterials serves the broader healthcare and biomedical device markets through products aimed at restoring tissue function and improving patient outcomes. The company is headquartered in Herzliya, Israel.

CEO Dr. Ehud Geller Ph.D. · 3 employees · Israel · https://www.regentis.co.il